Clinical trial with CIBA 1906 in lepromatous leprosy.
Drug trial with CIBA 1906 was conducted in 50 cases of lepromatous leprosy who were intolerant to dapsone therapy. Drug was tolerated well and lepra reactions were infrequent and mild. Clinical improvement was seen in 72% cases whereas no appreciable change was detected in 28% cases. An average reduction of 0.4 in BI was detected in 62% cases, while remaining cases did not show any reduction in BI. No significant side effects were encountered during the study. Antibacterial activity of CIBA 1906 was not found superior to dapsone.
D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D010670:Phenylthiourea / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D007917:Leprostatic Agents; D010670:Phenylthiourea; C100207:thiambutosine